Royalty Pharma Plc
RPRXLatest QuantConomy context for RPRX: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
Royalty Pharma Plc
Royalty Pharma PLC (RPRX) is the world's largest buyer of biopharmaceutical royalties, specializing in acquiring and managing revenue-generating intellectual property in the life sciences sector. The company has a diversified portfolio of royalties from over 35 commercial products, including market-leading therapies such as AbbVie and Johnson & Johnson's Imbruvica, Biogen's Tysabri, and Vertex's cystic fibrosis franchise. Royalty Pharma provides capital to biopharmaceutical companies in exchange for future revenue streams, offering a unique business model that diversifies risk and allows for participation in the growth potential of new drug discoveries. This model generates stable and predictable cash flow, enabling the company to reinvest in new opportunities and support its growth strategy. With strong relationships with major pharmaceutical companies and deep expertise in evaluating drug development projects, Royalty Pharma positions itself as a leader in funding innovation across the life sciences ecosystem.
- Symbol
- RPRX
- Name
- Royalty Pharma Plc
- Coverage
- 3 market/data records
- Sources
- alphavantage fmp alpaca sec nasdaq
Recent signals for RPRX
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| insider trade large sale | very bearish | 33 | Jun 25, 09:22 PM | Hite Christopher sold RPRX shares ($1.75M) - 32,408 shares - [very weak very bearish signal] |
| earnings earnings release | neutral | 40 | Feb 11, 12:00 AM | RPRX filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-02-11. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read). |
| price downtrend | slightly bearish | 20 | Jun 17, 04:26 PM | RPRX downtrend (drop): price -0.98% (strength 20, current 54.315) |
EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).
PRICE signals are experimental: realized 30-day directional accuracy is ~18% (short-horizon price moves tend to mean-revert). They are automatically down-weighted in composite scores but served raw here. Do not use them as standalone trade advice.
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| RPRX | NASDAQ | alphavantage | Royalty Pharma plc - Class A |
| RPRX | NASDAQ | fmp | Royalty Pharma plc |
| RPRX | NASDAQ | alpaca | Royalty Pharma plc Class A Ordinary Shares |
Recent insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | Urist Marshall | EVP, Research & Investments | sale | 9,098 | $55.18 | $502,067 | 4 on EDGAR |
| Jun 23, 2026 | Hite Christopher | EVP & Chairman, Partnering | sale | 32,408 | $54.11 | $1,753,500 | 4 on EDGAR |
| Jun 5, 2026 | Coric Vlad | Insider | grant | 4,545 | $0.00 | $0 | 4 on EDGAR |
| Jun 5, 2026 | Ho Carole | Insider | grant | 4,545 | $0.00 | $0 | 4 on EDGAR |
| Jun 5, 2026 | HODGSON DAVID C | Insider | grant | 4,545 | $0.00 | $0 | 4 on EDGAR |
| Jun 5, 2026 | LOVE TED W | Insider | grant | 4,545 | $0.00 | $0 | 4 on EDGAR |
| Jun 5, 2026 | Bassler Bonnie L | Insider | grant | 4,545 | $0.00 | $0 | 4 on EDGAR |
| Jun 5, 2026 | WEATHERMAN ELIZABETH H | Insider | grant | 4,545 | $0.00 | $0 | 4 on EDGAR |
| Jun 5, 2026 | Engelbert Catherine M. | Insider | grant | 4,545 | $0.00 | $0 | 4 on EDGAR |
| Jun 5, 2026 | Norden Gregory | Insider | grant | 4,545 | $0.00 | $0 | 4 on EDGAR |
| May 26, 2026 | Coyne Terrance P. | EVP & CFO | sale | 64,399 | $53.98 | $3,476,116 | 4 on EDGAR |
| May 20, 2026 | Urist Marshall | EVP, Research & Investments | sale | 13,684 | $52.75 | $721,838 | 4 on EDGAR |
| May 14, 2026 | Norden Gregory | Insider | sale | 3,045 | $53.00 | $161,385 | 4 on EDGAR |
| May 14, 2026 | Urist Marshall | EVP, Research & Investments | sale | 13,684 | $53.06 | $726,137 | 4 on EDGAR |
| May 6, 2026 | Urist Marshall | EVP, Research & Investments | grant | 18,197 | $0.00 | $0 | 4 on EDGAR |
| May 6, 2026 | Coyne Terrance P. | EVP & CFO | grant | 24,263 | $0.00 | $0 | 4 on EDGAR |
| May 6, 2026 | Hite Christopher | EVP & Vice Chairman | grant | 24,263 | $0.00 | $0 | 4 on EDGAR |
| May 6, 2026 | Legorreta Pablo G. | CEO, Chairman of the Board | grant | 143,821 | $0.00 | $0 | 4 on EDGAR |
| Apr 28, 2026 | Coyne Terrance P. | EVP & CFO | sale | 32,916 | $49.78 | $1,638,506 | 4 on EDGAR |
| Apr 1, 2026 | Coyne Terrance P. | EVP & CFO | sale | 1,875 | $48.33 | $90,622 | 4 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Query RPRX context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access